This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
by Zacks Equity Research
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
by Zacks Equity Research
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
REGNPositive Net Change NVSPositive Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
by Zacks Equity Research
Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.
GSKPositive Net Change PFEPositive Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore
by Zacks Equity Research
EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.
ALKSPositive Net Change EXELPositive Net Change VRNAPositive Net Change KNSAPositive Net Change
biotechnology biotechs
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
by Sundeep Ganoria
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
by Zacks Equity Research
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
AGENNegative Net Change VRNAPositive Net Change APLSPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
by Ahan Chakraborty
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
EXELPositive Net Change ALKSPositive Net Change VRNAPositive Net Change KNSAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
by Sundeep Ganoria
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
SNYPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs gene-editing gene-therapy medical messenger-rna pharmaceuticals
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
by Zacks Equity Research
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
VRTXPositive Net Change EXELPositive Net Change PBYINegative Net Change SPRONegative Net Change
biotechs
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
by Zacks Equity Research
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
EXELPositive Net Change PBYINegative Net Change RCKTNegative Net Change SPRONegative Net Change
biotechs
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
by Zacks Equity Research
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
BIIBPositive Net Change AGENNegative Net Change VRNAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
by Zacks Equity Research
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
GSKPositive Net Change NVSPositive Net Change QGENPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Moderna Stock Gains on Encouraging Flu Vaccine Data
by Zacks Equity Research
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
GSKPositive Net Change MRNANegative Net Change AGENNegative Net Change AMRNPositive Net Change
biotechs medical messenger-rna vaccines
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
by Zacks Equity Research
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
BAYRYPositive Net Change AGENNegative Net Change RAREPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
by Zacks Equity Research
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
EXELPositive Net Change PBYINegative Net Change SPRONegative Net Change VORPositive Net Change
biotechs
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
by Ahan Chakraborty
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for ADMA Biologics Stock Options
by Zacks Equity Research
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
ADMAPositive Net Change
biotechnology biotechs medical
Will Strong Asceniv Sales Drive ADMA Biologics Further?
by Ekta Bagri
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
GRFSPositive Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
by Zacks Equity Research
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechs
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
by Ahan Chakraborty
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
by Zacks Equity Research
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
SNYPositive Net Change GILDPositive Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
by Zacks Equity Research
Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.
BAYRYPositive Net Change AGENNegative Net Change KRYSPositive Net Change IMCRPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
by Zacks Equity Research
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
BAYRYPositive Net Change AGENNegative Net Change AMRNPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals